MDXH News & Events

Reports Q4 revenue $29.55M, consensus $26.02M. Michael McGarrity, CEO of mdxhealth, commented: "We are pleased to report another year of 20% revenue growth which reflects continued operating discipline and commercial execution by our team. Our consistent growth is a result of our strategy to build an incomparable menu of precision diagnostics for urologists and patients navigating the complex diagnostic pathway of prostate cancer."

Michael McGarrity, CEO of mdxhealth, commented: "We are pleased to report continued execution on our growth strategy, with Q4 and 2025 full year revenue growth exceeding 20%. We are confident that the strength of our sales channel coupled with our expanded menu offering to our urology customer base will continue to drive sustainable growth. Based on our operating discipline, commercial execution, and the underlying growth of our end markets, we anticipate 2026 revenue of $137-140 million, which would represent year-over-year revenue growth of approximately 26-28%. We also expect our focus on operating discipline to drive progress toward an adjusted EBITDA margin run rate of 10% exiting 2026."

Mdxhealth announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score, GPS, testing in the landmark UK ProtecT trial. This study is designed to establish GPS as the first genomic classifier supported by randomized clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progression and long-term treatment outcomes.